百合固金汤联合多西他赛及铂类药物治疗晚期非小细胞肺癌临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R734.2

基金项目:

甘肃省重点研发计划-社会发展类项目(18YF1FA047)


Clinical Study on Baihe Gujin Tang Combined with Docetaxe and Platinum Drugs for Advanced Non-Small Cell Lung Cancer
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察百合固金汤联合多西他赛及铂类药物治疗晚期非小细胞肺癌的临床疗效。方法:选取晚期非小细胞肺癌患者180 例,根据随机数字表法分为对照组和研究组各90 例。对照组给予多西他赛+卡铂方案化疗治疗,研究组在对照组的基础上加用百合固金汤治疗。2 组化疗疗程均为6 个周期,比较2 组临床疗效,比较2 组治疗前后细胞角蛋白19 可溶性片段(CYFRA21-1)、癌胚抗原(CEA)、糖类抗原125(CA125) 以及神经元特异性烯醇化酶(NSE) 水平,比较2 组治疗前后免疫球蛋白G、A、M(IgG、IgA、IgM) 水平及肺癌生活质量量表13(QLQ-LC13) 评分。结果:研究组临床疾病控制率(DCR)、客观缓解率(ORR) 分别为93.3%、74.4%,对照组分别为87.8%、56.7%,2 组比较,差异均有统计学意义(P<0.05)。治疗后,2 组血清CYFRA21-1、CEA、CA125、NSE 水平均较治疗前降低(P<0.05),且研究组各项指标均低于对照组(P<0.05)。治疗后,研究组IgG 水平与治疗前差异不大(P>0.05),对照组IgG 水平则较治疗前降低(P<0.05),研究组IgG 水平高于对照组(P<0.05);2 组IgA、IgM 水平均较治疗前降低(P<0.05),但研究组IgA、IgM 水平高于对照组(P<0.05)。治疗后,2 组QLQ–LC13 量表中一般症状、功能、肺癌症状评分均较治疗前降低(P<0.05),总健康状况评分较治疗前升高(P<0.05);其中研究组一般症状、肺癌症状2 项评分均低于对照组(P<0.05);而功能、总健康状况2 项评分与对照组比较,差异无统计学意义(P>0.05)。结论:多西他赛+卡铂方案联合百合固金汤治疗晚期非小细胞肺癌,可提高临床疗效,降低癌症肿瘤标志物水平,有效改善患者的生活质量及免疫功能。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Baihe Gujin tang combined with docetaxe and platinum drugs for advanced non- small cell lung cancer. Methods:A total of 180 cases of patients with advanced non- small cell lung cancer were divided into the control group and the study group according to the random number table method,with 90 cases in each group. The control group was treated with routine docetaxel+carboplatin chemotherapy,and the study group was additionally treated with Baihe Gujin tang based on the treatment of the control group. Both groups were treated for six weeks. The clinical effects in the two groups were compared. Before and after treatment,the levels of cytokeratin 19 fragment(CYFRA21- 1), carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),neuron-specific enolase(NSE),immunoglobulin G(IgG), immunoglobulin A(IgA),and immunoglobulin M(IgM) and the scores of Quality of Life Questionnaire-Lung Cancer 13(QLQLC13) in the two groups were compared. Results: The disease control rate(DCR) and objective response rate(ORR) were 93.3% and 74.4% in the study group and 87.8% and 56.7% in the control group,differences being significant(P<0.05). After treatment,the levels of CYFRA21-1,CEA,CA125 and NSE in serum in the two groups were decreased when compared with those before treatment(P<0.05), and the indexes in the study group were lower than those in the control group(P< 0.05). There was no significant difference being found in the comparison of IgG level in the study group before and after treatment(P>0.05), and the IgG level in the control group was decreased when compared with that before treatment(P< 0.05),and the IgG level in the study group was higher than that in the control group(P<0.05);the levels of IgA and IgM in the two groups were decreased when compared with those before treatment(P<0.05), and the levels of IgA and IgM in the study group were higher than those in the control group(P<0.05). After treatment, the scores of general symptoms, function and lung cancer symptom in QLQ- LC13 in the two groups were decreased when compared with those before treatment(P<0.05),and the total scores of health status were increased(P<0.05). The scores of general symptoms and lung cancer symptom in the study group were lower than those in the control group(P<0.05); and there was no significant difference in the comparison of function and total score of health status between the study group and the control group(P> 0.05). Conclusion: Docetaxel + carboplatin combined with Baihe Gujin tang for advanced non- small cell lung cancer can improve clinical effects,quality of life and immune function,and reduce levels of tumor markers.

    参考文献
    相似文献
    引证文献
引用本文

刘喜婷,吴玉强,杨磊,伏彩红.百合固金汤联合多西他赛及铂类药物治疗晚期非小细胞肺癌临床研究[J].新中医,2022,54(8):146-149

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-04-24
  • 出版日期: